The URO panel of antibodies was developed to immuno-anatomically dissect the nephron from glomerulus to bladder urothelium - these antibodies detect various cell surface antigens specific to segments of the renal tubule. Several have been shown to occur as tissue related markers of renal cancers. This antibody reacts predominantly with adherent cell types and is absent from cells growing in suspension, e.g. leukemia, lymphoma, lymphoblastoid, or other hematopoietic cell lines. In tissues, the URO1 antigen is expressed by glomeruli, the basal layer of transitional epithelium and skin, and the basement membrane of glands. All bladder tumors express URO1, as do most kidney tumors and other epithelial tumors (e.g. colon, ovary, lung and breast). Astrocytoma, melanoma, sarcoma, and lymphoma specimens are negative for URO1 expression.